US Patent 9,295,713
United States Patent and Trademark Office
Celldex Therapeutics, Inc. (Needham, MA, US) ; University of Iowa Research Foundation (Iowa City, IA, US)
A method is disclosed for treating nephropathies involving undesired alternative pathway complement activation by administration of a complement inhibitory protein such as soluble complement receptor type I (sCR1).
Creative Commons License
This work has been identified with a Creative Commons Public Domain Mark 1.0.
Smith, Richard J H; Zhang, Yuzhou; and Marsh, Henry C Treatment of chronic nephropathies using soluble complement receptor type I (sCR1). US Patent 9,295,713 filed September 15, 2011 and issued March 29, 2016. https://ir.uiowa.edu/patents/660